Systematic literature review: Quality of life associated with insulin pump use in type 1 diabetes

TY - JOUR

T1 - Systematic literature review

T2 - Quality of life associated with insulin pump use in type 1 diabetes

AU - Barnard, K. D.

AU - Lloyd, C. E.

AU - Skinner, T. C.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Aim: To review systematically the published literature addressing whether continuous subcutaneous insulin infusion (CSII) provides any quality of life benefits to people with Type 1 diabetes. Methods: Electronic databases and published references were searched and a consultation with two professional groups was undertaken to identify relevant studies published up to July 2005. A multistep selection process was then undertaken to identify those articles which met the specific selection criteria, which were then critically reviewed. Results: Eighty-four potential relevant articles were identified from examination of titles and abstracts published during the specified time frame. Of these, 28 articles were retrieved in full text, of which 17 fulfilled the specific criteria for inclusion. Mixed results emerged from existing literature. Of the five randomized controlled trials, three reported mixed results, with one study reporting quality of life benefits and one reporting no evidence of quality of life benefits. Conclusions: There is conflicting evidence reported in the various studies on the quality of life benefits of CSII in Type 1 diabetes. Existing research is flawed, making a judgement about the quality of life benefits of insulin pump use difficult. There is no strong evidence against quality of life benefits associated with CSII or otherwise, with poor methodology and inconsistent assessment of quality of life clouding the issue. The lack of reported benefit is probably a function of this rather than pump therapy not offering any quality of life benefits.

AB - Aim: To review systematically the published literature addressing whether continuous subcutaneous insulin infusion (CSII) provides any quality of life benefits to people with Type 1 diabetes. Methods: Electronic databases and published references were searched and a consultation with two professional groups was undertaken to identify relevant studies published up to July 2005. A multistep selection process was then undertaken to identify those articles which met the specific selection criteria, which were then critically reviewed. Results: Eighty-four potential relevant articles were identified from examination of titles and abstracts published during the specified time frame. Of these, 28 articles were retrieved in full text, of which 17 fulfilled the specific criteria for inclusion. Mixed results emerged from existing literature. Of the five randomized controlled trials, three reported mixed results, with one study reporting quality of life benefits and one reporting no evidence of quality of life benefits. Conclusions: There is conflicting evidence reported in the various studies on the quality of life benefits of CSII in Type 1 diabetes. Existing research is flawed, making a judgement about the quality of life benefits of insulin pump use difficult. There is no strong evidence against quality of life benefits associated with CSII or otherwise, with poor methodology and inconsistent assessment of quality of life clouding the issue. The lack of reported benefit is probably a function of this rather than pump therapy not offering any quality of life benefits.

KW - CSII

KW - Health outcomes

KW - Insulin pump

KW - Quality of life

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=34249333098&partnerID=8YFLogxK

U2 - 10.1111/j.1464-5491.2007.02120.x

DO - 10.1111/j.1464-5491.2007.02120.x

M3 - Review

C2 - 17367304

AN - SCOPUS:34249333098

SN - 1464-5491

VL - 24

SP - 607

EP - 617

JO - Diabetic Medicine Online

JF - Diabetic Medicine Online

IS - 6

ER -